GlassScriptPhysician profile
Mumnoon Haider
NPI 1326255308
$3,441.65
in general payments reported to CMS, 2019-2025
22 companies · $397 in 2025
The $397 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $483 · 2020: $343 · 2021: $685 · 2022: $521 · 2023: $653 · 2024: $360 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,391 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,390.51 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $829.85 | 2019-2025 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals LP | $360.41 | 2019-2024 | Farxiga, Lokelma |
| Amgen INC. | $325.21 | 2019-2025 | Tavneos, Aranesp, Parsabiv |
| Aurinia Pharma U.S., INC. | $267.15 | 2021-2022 | |
| Fresenius USA Marketing, INC. | $251.10 | 2019-2024 | Velphoro, Korsuva |
| Opko Pharmaceuticals, LLC | $211.42 | 2019-2025 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $196.50 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $119.72 | 2021-2024 | |
| Travere Therapeutics, INC. | $103.59 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $99.53 | 2019-2025 | Jynarque |
| Alexion Pharmaceuticals, INC. | $93.62 | 2023 | |
| Ani Pharmaceuticals, INC. | $80.67 | 2023-2025 | Purified Cortrophin Gel |
| Nevro Corp. | $80.33 | 2019 | |
| Medtronic, INC. | $68.40 | 2023 | Ellipsys Vascular Access System |
| Mallinckrodt Hospital Products INC. | $64.74 | 2023 | Acthar |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $55.75 | 2019-2020 | |
| Horizon Therapeutics Plc | $55.35 | 2019-2023 | Krystexxa |
| Veloxis Pharmaceuticals, INC. | $54.75 | 2020-2025 | Envarsus |
| Akebia Therapeutics INC | $33.19 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.56 | 2025 | Jardiance |
| Glaxosmithkline, LLC. | $31.03 | 2021-2024 | Jesduvroq, Benlysta |
| Arbor Pharmaceuticals, INC. | $26.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mumnoon Haider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.